0. Innovative Drug Delivery Solutions
We Make Approved Drugs Better
November 24, 2015
TSX-V: IGX OTCQX: IGXT

1. Forward Looking Statements
To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements.
Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities Commission. IntelGenx undertakes no obligation to update or revise any forward-looking statement.

2. Oral Thin Films Provide Significant Market Opportunities for Improving Drug Delivery
IGX CEO co-developer of the Listerine breath strips
Oral films ideal for elderly, children, patients who have difficulty swallowing traditional tablets
Quicker action to relieve symptoms

3. IntelGenx Drug Delivery Technology Platforms
Making Approved Drugs Better Through Innovative Drug Delivery Solutions
IntelGenx develops and manufactures faster and more efficient drug delivery systems for top pharmaceuticals
IntelGenx Drug Delivery Technology Platforms
Tablets
Films
Controlled-release tablets for oral absorption over an extended time period
Rapidly disintegrating film improving drug performance and easing administration without the need for water
Rizaport™

4. Investment Highlights
$17B TAM
Developing proprietary oral drug delivery technologies to address $19B TAM
Market momentum with Forfivo XL ® tablets
Achieved first European marketing approval of RIZAPORT™ for Migraines
Robust product pipeline to enable expansion into other market segments with significant TAM
Achieved record Q3 revenue and profitability
VersaTab™
$1.7B TAM

5. First 450mg tablet approved by FDA for major depressive disorder
FORFIVO XL®
Technology
First 450mg tablet approved by FDA for major depressive disorder
High dose version of Wellbutrin XL®
Only approved, once-daily, bupropion HCl 450mg dose in a single tablet
Launched commercially October 2013 in partnership with Edgemont Pharmaceuticals
Q net sales grew 16% compared to Q2 2015, with net sales at $2.5 million ($4.7 million gross)
For the past nine months, net sales totaled $6.3 million ($12 million gross), an increase of 117% compared to the nine month period in 2014
FORFIVO XL® NET SALES ($Thousands)
$3,000
$2,500
$2,132
$2,000
$1,756
$1,697
$1,195
$1000
3Q14
4Q14
1Q15
2Q15
3Q15

6. Oral Thin Films Drug Delivery Technology
Over $17B Market Opportunity and Growth Platform for IGX
Benefits of VersaFilm™
Improves patients compliance who have problems swallowing tablets and capsules to more easily take medication
Rapid disintegration without the need for water
Improves absorption – faster onset of action
Potential for reduced adverse effects
$17B Addressable Market
Successful pivotal bioequivalence studies
Two film products awaiting FDA approval
Limited number of competitors
OPIOD DEPENDENCE
Targeted Suboxone Sales
$1.7B
SCHIZOPHRENIA Targeted Sales
$5.2B
MIGRAINE
Targeted Rizatriptan Market
$2B
ERECTILE DYSFUNCTION
Targeted Cialis® Sales
$4.2B

7. Leverages VersaFilm™ Technology to Treat Migraines
Rizaport™
Leverages VersaFilm™ Technology to Treat Migraines
European Mktg Approval – November 2015
Filed 505(b)(2) NDA - March 2013 for USA
Co-development partnership with RedHill Biopharma
Negotiations with commercialization partner ongoing

8. A Robust Product Pipeline to Address Significant Market Opportunities
Indication
Market Opportunity
Partnering Availability
Formulation Development
Pilot Study
Pivotal Study
Filing
Launch
Films
Migraine – Rizaport TM - Rizatriptan
$2B
Available
Erectile Dysfunction - Tadalafil
$4.2B
Opioid Dependence – Buprenorphine & Naloxone
$1.78B
Par Pharmaceuticals
Schizophrenia
$5.2B
Undisclosed
N/A
Pain
$100M
Central Nervous System
2.7B
1.1B
Respiratory
77M
Cardiovascular
Tablets
Major Depressive Disorder – Forfivo XL®
Bupropion
400M
Edgemont Pharmaceuticals
Available ex-USA
Hypertension - Metoprolol
1.2B
Pain - Dronabinol
130M

9. Commercialization Initiatives Strategic Partnerships Will Drive Growth9

10. In-House Manufacturing Approach
Full Manufacturing Capabilities Establishing manufacturing capability to increase profitability
Integrate pharmaceutical services and IP protection
Reduce dependence by IntelGenx on external manufacturing partners
Offer clients the advantage to obtain all services from one source (“one-stop shopping”)
Increase R&D capabilities with expanded laboratories and technologies
Blending
Coating
Packaging

11. Future Commercialization Strategy Key milestones suggest near term catalysts
2017
2016
Milestones
Anticipated approval for opioid dependence VersaFilm™
Anticipated submission of 505(b)(2) NDA for ED VersaFilm™
Anticipated approval for migraine – USA FDA, Rizaport™
Milestones
Anticipated launch for opioid dependence VersaFilm™
Anticipated approval for ED VersaFilm™
Start of commercial manufacturing operations
Anticipated submission of 505(b)(2) NDA for Schizophrenia VersaFilm™
FORFIVO XL® milestone payments anticipated

12. Record Results in Q3 Demonstrates Strong Execution of Strategy
Revenue ($M) $M

13. Record Results in Q3 Demonstrates Strong Execution of Strategy
Net Income & Adjusted EBITDA ($M) $M

14. Visionary, Experience Leadership
100+ years of combined industry experience
Horst G. Zerbe, Ph. D.
Chairman, President & CEO
Co-Founder of Listerine breath strips
30+ years drug delivery / pharma experience
Holds over 40 patents in drug delivery and numerous scientific publications
André Godin, CPA, CA
Executive VP, CFO
25+ years biotech/pharma industry experience
Member of the Canadian Chartered Professional Accountants and the Canadian Institute of Chartered Accountants
Nadine Paiement, M. Sc.
Director R&D
Co-inventor of IntelGenx Trilayer Technology
15 years experience in product development and technology transfer
John Durham, B. Sc.
VP, Manufacturing Operations
20+ years experience in pharmaceutical manufacturing, quality management, product development
Held executive positions with several Canadian and US companies
Laëtitia Rodes, Ph. D.
Manager, BD
7+ years experience in medical R&D
Ph. D. In Biomedical Engineering (McGill University)
Numerous peer-reviewed scientific publications (17+)
Edward Miller, B. Comm Director, Investor Relations
15 years experience in investor relations
10 + years experience in pharmaceutical / biotech
Currently 18 Employees, 8 Ph.D.’s

15. Solid Platform for Growth Core Technologies Address $19B Market Potential
Continue to grow commercialization efforts of Forfivo XL® to drive revenue growth
Advance product pipeline towards commercialization
Continue to develop distribution channel relationships
Leverage VersaFilm manufacturing expertise to enhance profitability

16. Thank You.